Stage II Non-Small Cell Lung Cancer Clinical Trial
Official title:
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
This pilot clinical trial studies stereotactic body radiation therapy followed by combination chemotherapy in treating patients with non-small cell lung cancer. Stereotactic body radiation therapy is a specialized radiation therapy that delivers one to five high doses of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue than conventional radiation. Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving stereotactic body radiation therapy, followed by carboplatin, and paclitaxel albumin-stabilized nanoparticle formulation may kill more tumor cells and result in a better and more durable response than conventional radiation and chemotherapy. The purpose of this study is to test the safety of this approach prior to larger studies.
PRIMARY OBJECTIVES:
I. To determine the safety/feasibility of delivering chemotherapy after definitive
stereotactic body radiation therapy (SBRT) for selected stage/situations of non-small cell
lung cancer (NSCLC).
SECONDARY OBJECTIVES:
I. To determine the 1-year progression free survival in the sub-population of patients with
stage IB/II NSCLC, i.e. the "curative intent" subgroup of patients.
OUTLINE:
Patients undergo stereotactic body radiation therapy every other day for up to 14 days for a
total of 5 fractions. After a break period of about 30 days, patients will then start
chemotherapy. Patients will receive carboplatin intravenously (IV) over 30-40 minutes on day
1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days
1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease
progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 1 year.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
| Terminated |
NCT00369551 -
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03433469 -
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
|
Phase 2 | |
| Completed |
NCT03366766 -
Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT02823990 -
TG4010 and Nivolumab in Patients With Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02621398 -
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
|
Phase 1 |